DCAL167.18

Dishman Carbogen Amcis Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersHIKALSOLARAPANACEABIOINDSWFTLABSAIPARENTINDOCOSMSPHARMAWINDLASMcap ₹2,621 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations2,615.82,711.52,931.92,901.5
Other Income28.221.755.949.4
Total Income2,644.02,733.22,987.82,950.8
Expenses
+ Cost of Materials Consumed601.2593.0487.9426.9
+ Changes in Inventories-4.0-91.3-79.1-2.0
+ Employee Benefit Expense1,208.21,293.61,446.91,484.1
+ Finance Costs120.0159.5174.2168.5
+ Depreciation & Amortisation310.9293.7338.7348.0
+ Other Expenses523.9447.3510.6507.4
Total Expenses2,760.12,695.82,879.12,933.0
EBITDA286.5468.9565.6485.0
EBIT-24.4175.2226.9137.0
Profit
PBT before Exceptional Items-116.137.4108.717.9
+ Exceptional Items-6.1-18.1-3.8-2.8
Pretax Income-122.319.3104.915.0
+ Current Tax54.243.859.143.8
+ Deferred Tax-23.0-27.7-51.6-44.9
Tax Expense31.216.17.5-1.2
Net Income-153.53.297.516.2
+ Net Income — Continuing Ops-153.53.297.516.2
+ Other Comprehensive Income-28.8200.8747.9438.6
Total Comprehensive Income-182.2204.0845.4454.8
Net Income to Common-153.53.297.516.2
Per Share
Basic EPS-9.790.216.221.03
Diluted EPS-9.790.216.221.03
Other Comprehensive Income — detail
+ Other Comprehensive Income200.8747.9438.6
+ Items NOT to be Reclassified to P&L-116.826.237.337.2
+ Tax on Items NOT to be Reclassified-3.311.511.4
+ Tax on Items NOT to be Reclassified — alt tag0.1
+ Items to be Reclassified to P&L96.0167.8691.3408.3
+ Tax on Items to be Reclassified-3.6-30.7-4.5
+ Tax on Items to be Reclassified — alt tag7.8
Comprehensive Income — Owners of Parent-182.2204.0747.9425.6
Comprehensive Income — Non-controlling Interests0.0845.4391.6
Per Share — as-filed variants
Basic EPS — Continuing Operations-9.790.216.221.03
Diluted EPS — Continuing Operations-9.790.216.221.03
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit2,018.62,209.92,523.12,476.6
Gross Margin %77.1781.5086.0685.35
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-116.137.4108.717.9
− Exceptional Items (reconciliation)-6.1-18.1-3.8-2.8
Net Income Adj (tax-effected)-147.310.5101.019.0
EPS Adj-9.400.686.451.21
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Filed Debt Equity0.000.000.000.00
Filed Dscr0.020.020.010.01
Filed Iscr0.030.030.030.03
Paid Up Equity Capital31.431.431.431.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.